Preterm Birth Prevention and Management Market Size (2024 - 2029)

The preterm birth prevention and management market is anticipated to experience growth, driven by an increasing demand for drugs and a focus on targeted therapies and standard care. The COVID-19 pandemic highlighted the need for effective prevention and management strategies, as the virus heightened risks associated with preterm births. Despite the challenges posed by drug-related adverse effects, the market is expected to expand due to ongoing research and development efforts, supported by increased funding. This growth trajectory reflects the rising awareness and need for solutions to address preterm birth complications.

Market Size of Preterm Birth Prevention and Management Industry

Preterm Birth Prevention and Management Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2021 - 2022
CAGR 5.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Preterm Birth Prevention and Management Market Major Players

*Disclaimer: Major Players sorted in no particular order

Preterm Birth Prevention and Management Market Analysis

The preterm birth prevention and management market is expected to register a CAGR of 5.4% over the forecast period.

The COVID-19 pandemic adversely affected treatment and therapies other than COVID-19 since the onset of the outbreak, which significantly impacted the preterm birth prevention and management market. However, preterm birth, premature membrane rupture, and, in rare instances, maternal mortality were among the risks that were heightened by COVID-19 infection during pregnancy. As a result, preterm birth prevention and management therapies were increased to prevent prenatal births and reduce complications. Moreover, in August 2021, a study conducted by researchers at UC San Francisco found that women who contract COVID-19 while pregnant had an increased risk of having any preterm delivery as well as a severe preterm birth. People who had a COVID-19 infection at some point during their pregnancy had a 60% increased risk of having an extreme preterm delivery (birth before 32 weeks) and a 40% increased risk of giving birth before 37 weeks (all preterm births). Preterm birth risk increased by 160% in people who also had COVID-19, hypertension, diabetes, and/or obesity. Another study by the Regents of the University of Minnesota in November 2020 that monitored birth and infant outcomes in 4,442 pregnant women infected with the coronavirus and their 4,527 fetuses and new-borns suggested that of the 3,912 infants with known gestational ages conceived by the pregnant women with COVID-19, 12.9% were born preterm (before 37 weeks gestation), compared with an estimated national rate of 10.2%. Of the 610 new-borns with coronavirus test results, only 2.6% were positive, most of them born to women with active infections at delivery. This greatly highlighted the demand for proper preterm birth prevention and management amid COVID-19, as per the analysis. Moreover, with the growing number of vaccinations, the post-pandemic phase observed positive market growth. For instance, the impact of the COVID-19 vaccination on preterm births was analyzed by several researchers globally. A study report published by the BMJ Publishing Group in August 2022 stated that the COVID-19 vaccination is not associated with a higher risk of preterm birth, small for gestational age at birth, or stillbirth. Hence, as per the study, the market is expected to witness stable growth over the coming years.

Certain factors that are driving the market's growth include the increasing need for preterm birth prevention and management drugs and a growing focus on targeted therapies and standard of care. The increasing need for preterm birth prevention and management drugs depends on the increasing number of cases of preterm birth in various regions and groups. As per the 2022 update report of the National Preterm Birth Prevention Collaborative, Safer Care Victoria, in Australia, one in every 12 pregnancies ends prematurely every year, and more than 26,000 babies are born too early. Thus, the increase in preterm births among various groups is expected to augment market growth during the study period.

Furthermore, the growing focus on research activities on therapies for preterm births is expected to drive market growth over the analysis period. For instance, as per NIH 2022, the estimated funding for research on preterm birth, low birth weight, and the health of the newborn in 2021 and 2022 was USD 455 million and USD 478 million, respectively. Thus, the rise in the funding of research is expected to lead to advanced prevention and management products that can drive the market over the forecast period.

However, the adverse effects associated with drugs used for preterm births are likely to hinder the growth of the market.

Preterm Birth Prevention and Management Industry Segmentation

As per the scope of the report, the preterm birth prevention and management market report covers various therapies which prevent and manage preterm birth. It is defined as babies born alive before 37 weeks of pregnancy are completed. There are sub-categories of preterm birth based on gestational age, i.e., extremely preterm (less than 28 weeks), very preterm (28 to 32 weeks), and moderate to late preterm (32 to 37 weeks). The Preterm Birth Prevention and Management Market is Segmented by Therapy Type (Progesterone Therapy, Corticosteroid Therapy, Tocolytics Therapy, Antibiotics Therapy, Heparin Profylaxis Therapy, and Others), Route of Administration (Oral, Parenteral, and Vaginal), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Therapy Type
Progesterone Therapy
Corticosteroid Therapy
Tocolytics Therapy
Antibiotics Therapy
Heparin Profylaxis Therapy
Others
By Route of Administration
Oral
Parenteral
Vaginal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Preterm Birth Prevention and Management Market Size Summary

The preterm birth prevention and management market is poised for steady growth, driven by an increasing need for effective therapies and a focus on targeted treatments. The COVID-19 pandemic initially disrupted the market, but it also highlighted the critical need for preterm birth prevention as infections during pregnancy were linked to higher risks of preterm deliveries. This led to a surge in demand for prevention and management strategies. The post-pandemic phase has seen positive market momentum, supported by research indicating that COVID-19 vaccinations do not increase the risk of preterm births. The market's expansion is further fueled by the rising incidence of preterm births globally, prompting a greater emphasis on research and development of advanced therapies.

North America is expected to hold a significant share of the market due to the high prevalence of preterm births and the presence of advanced healthcare infrastructure. The region's demand for preterm birth prevention medications is bolstered by technological advancements and regulatory developments, such as the US FDA's discussions on Makena, a treatment aimed at reducing preterm births. The market is moderately competitive, with major players like AbbVie Inc., Bayer AG, and Pfizer Inc. holding substantial shares. These companies are actively involved in research and development, as evidenced by recent approvals and initiatives aimed at addressing preterm birth challenges. Overall, the market is set to grow, driven by the increasing need for effective prevention and management solutions.

Explore More

Preterm Birth Prevention and Management Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Need for Preterm Birth Prevention and Management Drugs

      2. 1.2.2 Growing Focus on Targeted Therapies and Standard of Care

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects Associated with Medication

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Therapy Type

      1. 2.1.1 Progesterone Therapy

      2. 2.1.2 Corticosteroid Therapy

      3. 2.1.3 Tocolytics Therapy

      4. 2.1.4 Antibiotics Therapy

      5. 2.1.5 Heparin Profylaxis Therapy

      6. 2.1.6 Others

    2. 2.2 By Route of Administration

      1. 2.2.1 Oral

      2. 2.2.2 Parenteral

      3. 2.2.3 Vaginal

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Preterm Birth Prevention and Management Market Size FAQs

The Preterm Birth Prevention and Management Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)

Covis Pharma GmbH. (AMAG Pharmaceuticals, Inc.), Ferring B.V., Pfizer Inc., Takeda Pharmaceutical Company Limited. and ObsEva are the major companies operating in the Preterm Birth Prevention and Management Market.

Preterm Birth Prevention & Management Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)